We share ‘Progress’ our monthly newsletter with our community at large. If you have a story, questions or topics of interest you’d like read about, please contact us, as we’d love to hear from you.
Send an email to admin@fshdglobal.org.
ARM-201 has completed preclinical studies and successful pre-IND engagement with the U.S. Food and Drug Administration (FDA) and has received both Orphan Drug and Rare Paediatric Disease designations. They are now scaling for clinical studies.
FSHD Global Research Foundation in Sydney is excited to announce it has invested in miRecule’s second generation drug development program
FSHD Global’s own Emma Weatherley was featured on an episode of Radio National Breakfast where she shared her personal story
SEOUL, South Korea, July 06, 2026 (GLOBE NEWSWIRE) — NovMetaPharma Co., Ltd. (“NovMetaPharma” or “NMP”), a clinical-stage biopharmaceutical company that
Epicrispr trial using Springbok AI twin shows positive clinical evidence of increased lean muscle, including results from an Australian site
This method improves sensitivity and helps broaden the definition of genetic FSHD to more accurately correspond to clinical FSHD, allowing identification of those at risk in affected families and in large population studies.
Encouraging news from the Avidity/Novartis trial using targeted siRNA to suppress DUX4 in FSHD. The therapy, del-brax, is an investigational
FSHD Global was pleased to join Muscular Dystrophy Queensland for a webinar covering the latest developments in FSHD research and
A review of the pioneering research that uses MRI scans and AI to enable clinical trials for FSH muscular dystrophy and other neuromuscular conditions.
Project Mercury was established in 2023 to address critical challenges for clinical trials – ensuring safe and effective treatments reach patients quickly, equitably, and at scale.
